RESEARCH TRIANGLE PARK, N.C. (January 17, 2017) – Trials performed during another crop year have confirmed the yield benefit seen in prior years with ILeVO seed treatment across U. S. soybean growing states. Both demo and university trials measured a yield benefit in fields with varying levels of Soybean Sudden Death Syndrome (SDS) and Soybean Cyst Nematode (SCN) pressure. SDS and SCN are two top soybean yield robbers and are present in almost every soybean growing state.
Topline results from 2011-2016 university trials show that 2016 ILeVO yield increases are on par with the past four-year average of 4.7 bu/A. SDS trials across 21 variety locations report an average yield increase of 4.7 bu/A in 2016. Yield increases were even greater than 10 bu/A at sites with higher levels of disease infestations.
Across soybean growing states, 304 demo trials were executed to measure the ILeVO yield benefit on a range of plots. Side-by-side demos saw an average yield increase of 3 bu/A, while demos with documented visual symptoms showed an average yield benefit of 3.7 bu/A. Even demos without documented visual symptoms of SDS showed an average yield benefit of 2.7 bu/A.
“We’re proud to see that ILeVO is continuing to perform consistently in 2016,” said Jeremiah Mullock, Bayer seed treatment product development. “It’s important to note that our 304 demo trials reported a 76 percent positive response. It shows that the yield benefit appeared across the trials and not just in a few plots. ILeVO is continuing to demonstrate its return value for growers across varying levels of disease pressure.”
Bayer is committed to bringing new technology and solutions for agriculture and non-agricultural uses. For questions concerning the availability and use of products, contact a local Bayer representative, or visit Crop Science, a division of Bayer, online at www.cropscience.bayer.us.
Visit the Bayer Connect - Social Hub for social media, recent news, blog posts, videos and more from Crop Science, a division of Bayer.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Bayer Media Hotline, 1-862-404-5118, or
Linda Arnold Whaley
Crop Science, a division of Bayer
Tel: (919) 549-2836
Rhea + Kaiser
Tel: (630) 955-2603
Find more information at www.cropscience.bayer.us.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
© 2016 Bayer CropScience LP, 2 TW Alexander Drive, Research Triangle Park, NC 27709. Always read and follow label instructions. Bayer, the Bayer Cross and ILeVO are registered trademarks of Bayer. For additional product information, call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our website at www.cropscience.bayer.us.